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Abstract
Agriculture industry workers are at a higher risk for chronic bronchitis and obstructive pulmonary 
diseases, and current therapeutics are not entirely effective. We previously found that the 
specialized pro-resolving lipid mediator (SPM) maresin-1 (MaR1) reduced pro-inflammatory 
cytokine release and intracellular adhesion molecule-1 (ICAM-1) expression in bronchial 
epithelial cells exposed to extracts of organic dust (DE) derived from swine confinement facilities 
in vitro. The objective of this study was to determine whether MaR1 is effective at limiting lung 
inflammation associated with acute and repetitive exposures to DE in an established murine model 
of inhalant dust exposures. C57Bl/6 mice were treated with MaR1 or vehicle control and 
intranasally instilled with DE once or daily for 3 weeks. Bronchial alveolar lavage fluid was 
analyzed for total and differential cell counts and pro-inflammatory cytokine levels, and lung 
tissues were assessed for histopathology and ICAM-1 expression. In both single and repetitive DE 
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exposure studies, MaR1 significantly decreased bronchoalveolar lavage neutrophil infiltration, 
IL-6, TNF-α, and CXCL1 levels without altering repetitive DE-induced bronchiolar/alveolar 
inflammation or lymphoid aggregate formation. Lung tissue ICAM-1 expression was also reduced 
in both single and repetitive exposure studies. These data suggest that MaR1 might contribute to 
an effective strategy to reduce airway inflammatory diseases induced by agricultural-related 
organic dust environmental exposures.
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Introduction
In agricultural industries, organic dust exposure triggers significant airway inflammation. A 
one-time or acute exposure to these organic dust environments can result in acute lung 
injury, asthma-like symptoms, or organic dust toxic syndrome (1-3). Long-term exposures 
such as those experienced by individuals employed in concentrated animal feeding 
operations (CAFOs) lead to chronic bronchitis and obstructive pulmonary diseases (4-8). 
Acute exposures to organic dusts such as those found in swine CAFOs result in pro-
inflammatory cytokine release, including IL-6 and TNF-α, and neutrophil chemoattractants, 
coinciding with the influx of neutrophils in humans and rodents (9,10). Similarly, repeated 
organic dust exposures in humans and animal models demonstrate a persistence of airway 
inflammatory indices, albeit dampened, with evidence of lung histopathologic changes. It is 
recognized that persons with chronic exposures are at a heightened risk for lung function 
decline and chronic respiratory diseases, including chronic bronchitis and obstructive 
pulmonary disease (11-13). Building ventilation is thought to be a primary means of 
reducing respiratory health risks, although these engineering interventions are often not 
sufficient for protection against dust-induced airway inflammation and disease (3). While 
ventilator masks are effective at preventing disease, this method of prevention is 
inconsistently utilized by the susceptible populations (14). Furthermore, currently available 
therapeutics, including corticosteroids and β2 adrenergic receptor agonists, do not adequately 
treat or alleviate disease (8). More effective preventative and treatment strategies are 
required to improve the health of affected individuals.
The health benefits of diets high in ω-3 fatty acids are increasingly recognized (15-19), 
although the mechanisms underlying these benefits are not well understood. Recently, ω-3 
fatty acid-derived specialized pro-resolving mediators (SPM) have been linked to 
mechanisms underlying the anti-inflammatory benefits of ω-3 fatty acids (20-23). For 
example, the SPM resolvin E1 was found to lower inflammatory cytokines during acute lung 
injury, to limit lymphocyte recruitment, and to reduce airway hyper-responsiveness in a 
murine asthma model (24,25). In preclinical investigations, treatment with the SPM resolvin 
D1 diminished lipopolysaccharide-induced lung inflammation, as well as cigarette smoke-
induced lung inflammation in mice (26,27). In the case of the SPM maresin-1 (MaR1), 
reduced neutrophil infiltration and increased macrophage phagocytic capacities were 
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demonstrated in a murine peritonitis model, and pulmonary edema, neutrophil influx, and 
pro-inflammatory mediator production were reduced in MaR1-treated mice in a 
lipopolysaccharide-induced acute lung injury model (28,29). In a murine model of acute 
lung injury, MaR1 was found to decrease lung neutrophils, edema, and pro-inflammatory 
mediators (30). Furthermore, we found that MaR1 is effective in reducing pro-inflammatory 
responses associated with organic dust exposures in vitro. Namely, MaR1 treatment reduced 
protein kinase C (PKC)-ε and PKC-α activities, serum response element binding activities, 
and pro-inflammatory cytokine release in airway epithelial cells and ex vivo murine lung 
slice cultures exposed to organic dust extracts derived from swine confinement facilities 
(DE) (31) .
Based on these data, we hypothesized that treatment with MaR1 would diminish the airway 
inflammatory consequences induced by organic dusts in vivo. To test this hypothesis, we 
utilized an established murine model of single and repetitive DE treatment-induced airway 
inflammation (13). In this model, we assessed the effect of MaR1 pretreatment prior to 
single and repetitive DE exposures on cellular infiltration, pro-inflammatory cytokine 
release, expression of the adhesion molecule ICAM-1 in airway epithelial cells, and lung 
histopathology. MaR1 reduced DE-induced pro-inflammatory cytokine release, neutrophil 
influx, and epithelial cell ICAM-1 expression. Although, it did not significantly alter DE-
induced lymphoid aggregate formation and peribronchiolar/perivascular inflammation in the 
lung parenchyma. The results of these studies suggest a potential role for SPM like MaR1 in 
modulating airway inflammation associated with agriculture exposures. SPM may represent 




7(S)-Maresin-1 (7S,14R-dihydroxy-4Z,8E,10Z,12Z,16Z,19Z-docosahexaenoic acid) and 
7(R)-Maresin-1 (7R,14S-dihydroxy-4Z,8E,10E,12Z,16Z,19Z-docosahexaenoic acid) were 
purchased from Cayman Chemical (Ann Arbor, MI, USA).
Preparation of DE
DE was prepared as previously described (32). Briefly, settled dust from local swine 
confinement facilities was collected. Dusts were suspended in Hank’s Buffered Saline 
Solution (HBSS) at 1 g dust per 10 ml HBSS, and incubated at room temperature for 1 hr. 
The aqueous extract was centrifuged twice at 4250g for 20 minutes each and the resulting 
supernatant was sterile filtered (0.22 μm), which also removes coarse particles. The final 
solution, representing 100% aqueous DE, was frozen into aliquots and stored at −20 C. In 
these investigations, we have utilized two different lots of DE (collected on different dates) 
as well as different preparations; no lot-to-lot or preparation-induced variability was 
detected.
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Animal Care and Housing
Male C57Bl/6 mice of 6-8 weeks in age were obtained from Jackson Laboratories (Bar 
Harbor, ME, USA) and housed under pathogen-free conditions in group-housing cages. 
Mice were fed ad libitum a standard mouse chow diet and water. The University of 
Nebraska Medical Center Animal Care Facilities supervised the health and diet of mice, and 
all experiments performed were regulated and approved by the University of Nebraska 
Medical Center Institutional Animal Care and Use committee.
In Vivo DE Exposure Model
In vivo murine studies were performed using a standardized established model of organic 
dust exposure that has been previously characterized. (13, 33, 34) For single (1-time) 
exposure studies, mice were given ethanol vehicle (2 × 10−6 % ethanol in PBS), 0.1, or 1 ng 
MaR1 as a 50 l intraperitoneal (i.p.) injection at 18 hours before and 30 minutes prior to a 
single intranasal (i.n.) instillation consisting of 50 l of sterile saline solution or 12.5% DE. In 
an additional set of experiments, mice were given 1 ng MaR1 in a single 50 μl i.n. 
instillation prior to DE treatment as above. For repetitive exposure studies, mice were given 
ethanol vehicle (2 × 10−5 % ethanol in PBS) or 10 ng MaR1 i.p. 30 minutes prior to every 
i.n. instillation of saline solution or 12.5% DE for 15 consecutive weekdays. In all studies, 
individual groups consisted of a minimum of 5 mice each. At 5 hours following final DE 
instillation when cytokine release in the BALF peaks (13), mice were euthanized and BALF 
was obtained using 3 × 1-ml aliquots of phosphate-buffered saline (PBS). Lungs were 
subsequently inflated with formalin at a pressure of 20 cmH2O for 24 hours with formalin 
submersion to preserve pulmonary architecture.
Staining for Differential Cell Counts from BALF
BALF was centrifuged at 1500 rpm for 5 minutes to pellet cells. Following red blood cell 
lysis, total BALF cells numbers were enumerated by hemocytometer and cytospins of BALF 
cells were prepared using a Wescor CYTOPRO (Logan, Utah, USA). Slides were stained 
using Siemens Diff-Quik Stain Set (Newark, DE, USA). Differential cell counts were then 
quantified under light microscopy.
BALF Cytokines/Chemokines
The first 1 ml of BALF following centrifugation to remove cells was utilized for analyses. 
TNF-α, IL-6, CXCL1 and CXCL2 levels were quantitated using enzyme linked 
immunosorbant assays according to manufacturer’s directions (R&D Systems, Minneapolis, 
MN).
Tissue Histology
Inflated, formalin-fixed whole lungs were paraffin-embedded, microtome sectioned at 5 
microns, and stained with H&E utilizing standard processing, sectioning and staining 
techniques at the University of Nebraska Medical Center Tissue Sciences Facility. Whole 
lung microtome sections were reviewed and semi-quantitatively scored for the degree and 
distribution of inflammation by a lung pathologist blinded to treatment conditions, and 
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scores (0-3) were determined with the highest score representing maximal inflammation as 
previously described (13).
Immunohistochemistry
To determine epithelial cell ICAM-1 expression, unstained slides of sectioned (4-5 μm) lung 
were cleared with Protocol Safeclear II (Fisher Scientific, Kalamazoo, MI, USA) and 
rehydrated in an ethanol gradient. Antigen retrieval was performed using 2N HCl. Slides 
were blocked for 1 hour in a PBS-tween containing 5% w/v nonfat dry milk solution. Rat 
anti-mouse ICAM-1 antibody (Clone YN1/1.7.4; Biolegend, San Diego, CA, USA) was 
used a dilution of 1:75. Slides were incubated in primary antibody at 4° C overnight. 
Following 3 consecutive 5 minute washes in PBS-tween, slides were incubated for 1 hour in 
1:750 (goat) anti-mouse secondary antibody conjugated to biotin (Biolegend, San Diego, 
CA, USA) at room temperature. The Vector Labs ABC elite reagent kit and the Vector Labs 
ImmPACT DAB kit (Burlingame, CA, USA) were employed for visualization. Cells were 
counterstained with hematoxylin and blued with 0.1% sodium bicarbonate. Tissues were 
dehydrated, cleared, cover-slipped, and photographed under light microscopy.
Statistical Analyses
Statistical analyses were performed using Graphpad Prism software (La Jolla, CA, USA) 
and data are expressed as mean +/− the standard error of the mean. The ANOVA method 
was used for determining significance amongst all groups in an experiment, with Tukey’s 
method for post-hoc comparisons amongst groups to correct for the additional error rates 
that occurs with multiple groups/comparisons. A p value of less than or equal to 0.05 was 
considered to be a significant difference between two groups.
Results
MaR1 pretreatment reduces neutrophil influx and pro-inflammatory cytokine release 
following single exposures to DE
We have previously reported that a one-time exposure to DE in mice leads to marked 
neutrophil influx along with significant increases in TNF-α, IL-6, CXCL1 and CXCL2 in 
BALF (13). Pretreatment with 1 ng MaR1 prior to DE caused a reduction in total cell 
infiltration (Figure 1A) corresponding to a significant decrease in neutrophils compared to 
mice receiving vehicle + DE (Figure 1B, p < 0.05). Dose response studies with MaR1 at 
lower (0.1 ng) and higher (10 -1000 ng; data not shown) doses were conducted, and 1 ng 
MaR1 was the optimal dose in these acute exposure studies. While no toxicity was seen at 
higher MaR1 doses, it is of note that higher dose ranges at times resulted in increased 
inflammatory mediator production compared to vehicle + DE groups (data not shown), 
indicating a biphasic response. MaR1 has two different isoforms (7[S] and 7[R]) and 
isoform-specific effects have been described (35). Therefore, we tested the efficacy of both 
isoforms in our single exposure investigations. It is notable that at the 1 ng dose, the 7(R)- 
isoform of MaR1 did not reduce DE-induced neutrophil influx as the 7(S)-MaR1 isoform 
did (Figure 1B). Both isoforms of MaR1 significantly reduced the levels of DE-induced 
TNF-α, IL-6, and CXCL1 in the BALF (Figure 2A-C). Neither MaR1 treatment had a 
significant effect on DE-induced CXCL2 production (Figure 2D). There was no significant 
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difference between 1 ng 7(R)-MaR1 and 1 ng 7(S)-MaR1 when comparing DE-induced 
cytokine release; both were similarly effective at reducing TNF- α, IL-6, and CXCL1 levels 
in mice receiving a single instillation of DE (Figure 2).
In separate experiments, mice were given MaR1 via i.n. instillation 30 minutes prior to 
treatment with DE to determine whether route of administration would impact the effect of 
MaR1 on DE-induced airway inflammation. As shown in Figure 3A, treatment with i.n. 
7(S)-MaR1 blunted DE-induced total cell influx. This lower total cell infiltration correlated 
with a trend towards reduction in neutrophil influx, which was not significantly increased 
over saline controls (Figure 3B, p < 0.05). These findings were similar to the observations 
found with i.p. MaR1 treatment (Figure 1), whereby total and neutrophil infiltration were 
increased as compared to saline controls, but diminished when compared to vehicle + DE 
treated mice. Pretreatment with i.n. 7(S)- and 7(R)-MaR1 both reduced DE-induced IL-6 
and CXCL2, and TNF-α production was significantly lower in 7(R)-MaR1 + DE treated 
mice compared to DE-treated mice (Figure 4A, B, D). In 7(S)- or 7(R)-MaR1 + DE-treated 
mice, CXCL1 production was not significantly increased over saline-instilled controls 
(Figure 4C). Together, these data suggest a role for MaR1 in reducing the airway 
inflammatory responses following single DE exposures. Our data also indicate that 7(S) and 
7(R) isoforms of MaR1, as well as MaR1 administration route may modify effects in 
limiting airway inflammation associated with a single exposure to DE.
MaR1 pretreatment reduces neutrophil influx and pro-inflammatory cytokine release 
following repetitive exposure to DE
Repetitive exposure to DE in mice leads to neutrophil influx in the BALF, pro-inflammatory 
cytokine production, and peribronchial/vascular inflammation with lymphoid aggregate 
formation (13). In these studies, we sought to determine whether MaR1 treatment would 
reduce these established inflammatory consequences following repetitive DE exposures. For 
15 consecutive weekdays, mice were given 0 or 10 ng MaR1 by i.p. inoculation followed by 
i.n. instillation of DE. BALF and lung tissues were harvested five hours following the final 
DE exposures and assayed for markers of inflammation. MaR1 treatment decreased DE-
induced total cell and neutrophil influx significantly compared to mice receiving vehicle + 
DE (Figure 5). DE-induced TNF-α and CXCL1 BALF levels were decreased in animals 
receiving 7(S)- and 7(R)-MaR1 pretreatment as compared to vehicle control (Figure 6B, C), 
and DE-induced CXCL2 levels were reduced by 7(S)-MaR1 (Figure 6D). Although, there 
was no significant difference in alveolar or bronchiolar compartment inflammation or 
lymphoid aggregate formation in the 7(S)- or 7(R)-MaR1+DE-treated mice as compared to 
vehicle + DE control animals (Figure 7). It is notable that at lower and higher doses (0.1 – 1 
ng, 100 – 200 ng), MaR1 was not as effective as the 10 ng dose at altering the cellular influx 
and cytokine/chemokine production associated with the repetitive DE exposure (data not 
shown). These data suggest that MaR1 may be effective in reducing airway neutrophil and 
pro-inflammatory mediator release associated with DE exposures, but does not substantially 
attenuate DE-induced lung parenchymal histopathologic inflammatory changes.
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MaR1 pretreatment reduces DE-induced epithelial cell ICAM-1 expression following single 
and repetitive DE instillation
We have previously shown that DE treatment upregulates bronchial epithelial cell ICAM-1 
surface expression and increases neutrophil adhesion in vitro (36). In these studies, we have 
found that pretreatment with 1 ng 7(S)-MaR1 given i.p. prior to a single instillation of DE 
reduces DE-induced ICAM-1 expression on epithelial cells by immunohistochemistry 
staining techniques (Figure 8A-C). In addition, mice receiving 10 ng 7(S)-MaR1 in 
combination with repetitive DE exposures have reduced ICAM-1 expression in airway 
epithelial cells compared to mice receiving vehicle + DE (Figure 8D-F). Findings of reduced 
ICAM-1 surface expression were similar with 7(R)-MaR1 + DE single and repetitive 
treatments (data not shown). Together, these data show that MaR1 reduces DE-induced 
epithelial cell ICAM-1 expression that may, in part, explain the reduction in DE-induced 
neutrophilia found with MaR1 treatment.
Discussion
Through these studies, we have found a potential role for the SPM MaR1 in limiting the 
airway inflammatory consequences following organic dust exposures. Utilizing an animal 
model of organic dust exposure-induced lung disease, we have demonstrated that MaR1 
treatment significantly reduces the pro-inflammatory cytokine/chemokine release associated 
with single and repetitive exposures to DE. The findings of these investigations are 
summarized in Supplementary Summary Table I. In our studies, i.p. administration of MaR1 
resulted in significantly reduced neutrophil influx following both a one-time and repetitive 
DE exposure. Furthermore, DE-induced ICAM-1 expression was reduced in the epithelium 
of the airways with MaR1 treatment. Collectively, these data suggest SPM such as MaR1 
may hold potential for limiting the adverse effects of acute and repetitive organic dust-
induced airway inflammation.
Recent studies in the bioactive lipids field have revealed a role for the SPM derivatives of 
omega-3 fatty acids in resolving airway inflammation. Interestingly, it has been reported that 
diets high in poly-unsaturated fatty acids may significantly decrease mortality risk while 
improving clinical outcomes in patients experiencing acute lung injury or acute respiratory 
distress syndrome (37). We have recently demonstrated that treatment with the omega-3 
fatty acid docosahexaenoic acid for one week prior to a single DE exposure significantly 
reduced neutrophil influx and pro-inflammatory cytokine production (38). Yet, no previous 
studies have reported a role for SPM in organic dust-induced inflammation or identified the 
specific effects that MaR1 may influence during these lung inflammatory processes. MaR1 
is has been shown to be produced by neutrophil-platelet aggregates particularly during early 
stages of an inflammatory response, as well as by macrophages that are activated at sites of 
inflammation (28, 30). Neutrophil influx is a key marker of DE-induced airway and 
inflammation, and we have shown macrophages to be important during the resolution of 
organic dust-mediated effects (39). Additionally, our studies using a human bronchial 
epithelial cell line (BEAS-2B) and precision-cut mouse lung slices revealed MaR1 also acts 
on bronchial epithelial cells to limit pro-inflammatory responses to DE (31). These studies 
together indicate the potential utility of this dietary lipid derivative in modulating lung 
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inflammation, while illustrating the promise of using SPM such as MaR1 as treatments for 
lung inflammatory disease.
Our findings indicate that MaR1 pretreatment effectively reduces the DE-induced pro-
inflammatory cytokine/chemokine release seen with single and repetitive exposures to DE. 
Along with altering cytokine/chemokine production, MaR1 pretreatment correlated with 
blunted epithelial cell ICAM-1 expression and a moderate reduction in neutrophil influx into 
the airways in both our single and repetitive DE exposure models. These results corroborate 
with results found in murine models of peritonitis, colitis, and lipopolysaccharide-induced 
acute lung injury where MaR1 treatment reduced neutrophil influx and ICAM-1 expression 
(28, 29, 35, 40). The induction of ICAM-1 expression on airway epithelial cells during 
inflammatory insults is important for neutrophil functioning within the inflammatory lung 
environment (41, 42). The airway epithelium serves as a first responder during DE exposure 
by releasing pro-inflammatory cytokines and chemokines to recruit neutrophils into the 
airway while upregulating ICAM-1 on their surfaces to facilitate neutrophil target cell 
interaction (32, 41). Our results indicate that MaR1 is acting at multiple levels to affect this 
neutrophil functioning, by limiting neutrophil chemoattractants CXCL1 and/or CXCL2, 
reducing neutrophil influx, and lowering DE-stimulated epithelial cell ICAM-1 surface 
expression. These actions facilitated a reduction in the inflammatory environment of the 
lung and may be important measures in the prevention of adverse consequences associated 
with organic dust exposures.
While MaR1 appears to have significant effects on the neutrophil-mediated components of 
DE-induced airway inflammation, MaR1 did not have a significant effect on the 
peribronchiolar/perivascular inflammation or lymphoid aggregates that characterize the 
histopathology associated with our repetitive exposure model (13). MaR1 may not be 
dramatically affecting the recruitment and activation of lymphocytes associated with these 
inflammatory responses. We did however see a modest but significant increase in 
lymphocyte influx in the BALF of mice receiving 7(R)-MaR1 treatment along with 
repetitive DE exposure (Figure 5C). Investigations relating to the role of MaR1 in 
lymphocyte functioning during inflammatory responses is thus warranted. While MaR1 has 
been shown to affect neutrophils as well as macrophage phenotype and functioning during 
inflammation (26, 40), to our knowledge there is no documentation of MaR1 directly 
affecting lymphocyte response. Future studies investigating the role of MaR1 in these cell 
types will be valuable for deducing the role of this lipid mediator in modulating 
inflammation resolution.
A major feature of repetitive DE-induced airway inflammation is the presence of marked 
alveolar and bronchiolar inflammation along with the presence of lymphoid aggregates. 
MaR1 treatment during repetitive DE exposures did not significantly alter any of these 
histopathological features, even after increasing the dose of MaR1 given during the 
repetitive exposure studies up to 200 ng daily (data not shown). While we did not see 
significant changes in repetitive DE-induced histopathology with MaR1 treatment, MaR1 
may be more effective in accelerating the resolution phase following cessation of the DE 
exposures rather than limiting the persistent inflammation associated with ongoing repetitive 
exposures. Macrophages appear to be vital for regulating and limiting the exaggerated 
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inflammatory response associated with repetitive DE exposures (39), and MaR1 has been 
shown to induce an M2 macrophage phenotype that is important for inflammation resolution 
(26, 40). It is therefore plausible that MaR1 may act at the macrophage level following 
repetitive DE exposures to facilitate resolution. Future studies investigating this hypothesis 
may be warranted to provide insight into the role of MaR1 in the resolution of airway 
inflammation.
To further understand how MaR1 modulates airway inflammation during DE treatment, we 
examined the importance of administration route of MaR1 prior to i.n. DE treatment in our 
single DE exposure murine model. In one experimental design, MaR1 was given i.p. at 18 
hrs and 30 minutes prior to DE, while in a second design mice received MaR1 via i.n. 
instillation. An interesting difference in MaR1 administration route involved the mediator’s 
efficacy in reducing the murine IL-8 cognates CXCL1 and CXCL2. In single exposure 
studies, mice pretreated with MaR1 via i.p. administration, CXCL1 levels were decreased 
following DE exposure without impacting CXCL2, while mice pretreated with MaR1 via 
i.n. instillation did show significantly decreased CXCL2 (and CXCL1 levels were not 
significantly higher than saline controls). Thus, route of MaR1 administration may be 
important for elucidating the mediator’s full range of effects in the single exposure scenario. 
While CXCL1 and CXCL2 bind CXCR2 and are important neutrophil chemoattractants that 
are thought to have somewhat redundant affects, recently published data suggests these 
chemokines have different roles in regulating neutrophil recruitment, with both chemokines 
operating in the same pathway or event sequence (43). Reducing only one of these two 
neutrophil chemoattractants may thus still significantly alter the ability of neutrophils to 
migrate to the lungs.
The SPM MaR1 can be synthesized as two separate isomer formations, 7(S)-MaR1 and 
7(R)-MaR1, with 7(R)-MaR1 having been confirmed to be endogenously produced by 
macrophages in vivo during the resolution of murine peritonitis (28, 35). Because the 7(S)- 
and 7(R)- isomers of MaR1 have been shown to give differential effects (35), we assessed 
for selective effects with the two separate isomers of MaR1. In our model of acute DE 
exposure, we found that 7(S)-MaR1 pre-treatment resulted in decreased neutrophil 
recruitment to the lungs when given either i.p. or i.n. as compared to 7(R)-MaR1, while both 
isomers were similarly effective at reducing BALF pro-inflammatory cytokine levels and 
airway epithelial cell ICAM-1 expression. Although, when we assessed MaR1 isoform 
differences in our repetitive exposure model, we found that at the 10 ng MaR1 dose, the 
7(S)- and 7(R)-MaR1 isomers had similar efficacies in reducing neutrophil infiltration and 
pro-inflammatory cytokine release. These data suggest isomer-specific actions of MaR1 are 
present in the lungs particularly during acute inflammatory responses to DE. Of note, we did 
not investigate how utilizing a combined 7(S)- and 7(R)-MaR1 therapy might alter DE-
induced airway inflammation, although these investigations may be useful in better 
understanding MaR1 mechanisms of action.
With regards to mechanisms of action, other SPM have been found to bind and signal 
through G protein-coupled receptors to propagate their anti-inflammatory, pro-resolving 
effects (44). While there has been no specific receptor identified for MaR1 as of yet, it is 
highly plausible that MaR1 acts in a similar manner. Thus, the differing efficacies of 7(S)- 
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and 7(R)-MaR1 may be due to different binding efficiencies or characteristics of their 
interactions with cell surface receptors. Furthermore, certain SPM have been shown to bind 
to more than one receptor (44), and biphasic responses/efficacies were found in our own 
investigations (data not shown), as well as in other reported studies (45). Thus, it is possible 
that different binding efficacies at multiple receptors could explain some of the isomer-
specific or biphasic efficacies that are seen.
Taken together, these findings identify the potential of pro-resolving mediators such as 
MaR1 in limiting airway inflammation associated with acute and repetitive exposures to 
agricultural dusts. Pretreatment of MaR1 prior to DE exposure reduced lung neutrophil 
influx and pro-inflammatory cytokine production, while reducing ICAM-1 expression in 
airway epithelial cells. However, MaR1 did not impact the histopathological markers of 
chronic inflammation associated with repetitive DE exposure. These findings are highly 
relevant, because acute and repetitive exposures to organic dusts lead to harmful 
inflammatory cascades resulting in chronic disease; novel preventative and therapeutic 
modalities for treating these diseases are required. Clinical investigations indicate that 
modest decreases (of less than 50%) of certain cytokine levels in BALF/sputum correlate 
with disease severity and/or risk of death in diseases like chronic obstructive pulmonary 
disease and acute respiratory distress syndrome (46, 47). Thus, while MaR1 did not 
completely abrogate the lung inflammatory response to DE, the decreased inflammatory 
mediator production and neutrophil influx seen in our studies is likely to be biologically 
significant. While MaR1 did not alter the histologic measures of inflammation and lymphoid 
aggregate formation following repetitive DE exposure, its anti-inflammatory effect on 
BALF cytokine levels and neutrophil influx suggest it may be beneficial in an adjunctive 
therapeutic capacity. Furthermore, while MaR1 did not alter the histological features of 
repetitive DE-induced lung inflammation, it is possible that other SPM may better target this 
aspect of the airway inflammatory response to DE. Thus, future investigations are warranted 
to further understand the role of MaR1 and other SPM during acute and chronic organic dust 
exposures and how these lipid mediators might be exploited for use in treatment strategies 
for airway disease resulting from agricultural dust exposures.
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Background: Agricultural organic dust exposures trigger harmful airway inflammation, 
and agriculture workers are at risk for developing debilitating airway inflammatory 
diseases. Omega-3 fatty acid-derived specialized pro-resolving lipid mediators like 
maresin-1 promote the endogenous resolution of inflammation. These attributes make 
lipid mediators like maresin-1 attractive for use in preventing and treating inflammatory 
lung diseases.
Translational Significance: Our findings indicate a role for maresin-1 in reducing the 
severity of airway inflammation caused by organic dust exposures. These findings may 
contribute to novel strategies for preventing and treating airway inflammatory diseases in 
agriculture workers.
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Figure 1. Total and differential cell counts in BALF following single DE exposure in mice 
receiving pretreatment with MaR1 given intraperitoneally
Mice were pretreated with 0, 0.1, or 1 ng MaR1 given i.p. at 18 hrs and 30 minutes prior to a 
single intranasal treatment of DE. At five hours following DE exposure, BALF was 
collected. Mean total cell counts (A) and neutrophils and macrophages (B) are shown with 
standard error bars. ### p < 0.001 compared to vehicle + saline group; * p < 0.05 compared 
to vehicle + DE treatment group; N ≥ 5 mice per group.
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Figure 2. Pro-inflammatory cytokine levels in BALF following single DE exposure in mice 
receiving pretreatment with MaR1 given intraperitoneally
Mice were pretreated with 0, 0.1, or 1 ng MaR1 given i.p. at 18 hrs and 30 minutes prior to a 
single intranasal dose of DE. At five hours following DE exposure, BALF were retrieved 
and analyzed for IL-6 (A), TNF-α (B), CXCL1 (C), and CXCL2 (D) cytokine levels. ### p 
< 0.001 compared to vehicle + saline group; ## p < 0.01 compared to vehicle + saline group; 
# p < 0.05 compared to vehicle + saline group; *** p < 0.001 compared to vehicle + DE 
treatment group; ** p < 0.01 compared to vehicle + DE treatment group. Data are 
represented as mean values with standard error bars. N ≥ 5 mice per group.
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Figure 3. Total and differential cell counts in BALF following single DE exposure in mice 
receiving pretreatment with MaR1 given intranasally
Mice were pretreated with 0, or 1 ng MaR1 given i.n. at 18 hrs and 30 minutes prior to a 
single intranasal dose of DE. At five hours following DE exposure, BALF was recovered. 
Total cell counts were enumerated (A), as well as differential counts of neutrophils and 
macrophages (B). ### p < 0.001 compared to vehicle + saline group; ## p < 0.01 compared 
to vehicle + saline group; # p < 0.05 compared to vehicle + saline group. Data are 
represented as mean values with standard error bars. N ≥ 5 mice per group.
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Figure 4. Pro-inflammatory cytokine levels in BALF following single DE exposure in mice 
receiving pretreatment with MaR1 given intranasally
Mice were pretreated with 0 or 1 ng MaR1 given i.n. at 18 hrs and 30 minutes prior to a 
single intranasal dose of DE. At five hours following DE exposure, BALF were retrieved 
and analyzed for IL-6 (A), TNF-α (B), CXCL1 (C), and CXCL2 (D) cytokine levels. ### p 
< 0.001 compared to vehicle + saline group; ## p < 0.01 compared to vehicle + saline group; 
# p < 0.05 compared to vehicle + saline group; ** p < 0.01 versus DE treatment group; * p < 
0.05 versus DE treatment group. Data are represented as mean values with standard error 
bars. N ≥ 5 mice per group.
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Figure 5. Total and differential cell counts in BALF following repetitive DE exposures in mice 
receiving pretreatment with MaR1
Mice were pretreated with 0 or 10 ng MaR1 given i.p. 30 minutes prior to an intranasal dose 
of DE, given daily for 15 consecutive weekdays. At five hours following the final MaR1/DE 
exposure, BALF were retrieved. Total cell counts were enumerated (A), as well as 
differential counts of neutrophils and macrophages (B) and lymphocytes (C). ### p < 0.001 
compared to vehicle + saline group; ## p < 0.01 compared to vehicle + saline group; # p < 
0.05 compared to vehicle + saline group; *** p < 0.001 versus DE treatment group. Data are 
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represented as mean values with standard error bars. N ≥ 5 mice for control groups and N≥ 
10 mice for treatment groups.
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Figure 6. Pro-inflammatory cytokine levels in BALF following repetitive DE exposures in mice 
receiving pretreatment with MaR1
Mice were pretreated with 0 or 10 ng MaR1 given i.p. 30 minutes prior to an intranasal dose 
of DE, given daily for 15 consecutive weekdays. At five hours following the final MaR1/DE 
exposure, BALF were retrieved and analyzed for IL-6 (A), TNF-α (B), CXCL1 (C), and 
CXCL2 (D) cytokine levels. ### p < 0.001 compared to vehicle + saline group; ## p < 0.01 
compared to vehicle + saline group; # p < 0.05 compared to vehicle + saline group; *** p < 
0.001 versus Veh + DE treatment group; ** p < 0.01 versus Veh + DE treatment group; * p 
< 0.05 versus Veh + DE treatment group. Data are represented as mean values with standard 
error bars. N ≥ 5 mice for control groups and N≥ 10 mice for treatment groups.
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Figure 7. Lung histopathology following repetitive DE exposures in mice receiving pretreatment 
with MaR1
Mice were pretreated with 0 or 10 ng MaR1 given i.p. 30 minutes prior to an intranasal dose 
of DE, given daily for 15 consecutive weekdays. At five hours following the final MaR1/DE 
exposure, lungs were formalin-fixed and inflated for paraffin embedding and sectioning. 
Lungs were stained with hematoxylin and eosin (A), then scored by a lung pathologist for 
markers of chronic inflammation (B). ### p < 0.001 compared to vehicle + saline group. 
Data are represented as mean values with standard error bars. N ≥ 4 mouse lungs used in 
analyses for control groups and N ≥ 8 mice for treatment groups.
Nordgren et al. Page 22













Figure 8. ICAM-1 expression in airway epithelial cells following single or repetitive DE 
exposures in mice receiving pretreatment with MaR1
In single DE exposure studies, mice were pretreated with 0 or 1 ng MaR1 given i.p. at 18 hrs 
and 30 minutes prior to a single intranasal dose of DE. In repetitive DE exposure studies, 
mice were pretreated with 0 or 10 ng MaR1 given i.p. 30 minutes prior to an intranasal dose 
of DE, given daily for 15 consecutive weekdays. At five hours following final DE exposure, 
lungs were formalin-fixed and inflated for paraffin embedding and sectioning.
Immunohistochemistry was performed to assess ICAM-1 expression levels in airway 
epithelial cells following DE treatment with or without MaR1 pretreatment. Treatments: (A) 
single vehicle + saline, (B) single vehicle + DE, (C) single 1 ng 7(S)-MaR1 + DE, (D) 
repetitive vehicle + saline, (E) repetitive vehicle + DE, (F) repetitive 10 ng 7(S)-MaR1 + 
DE, (G) Secondary antibody only control. N ≥ 3 mouse lungs used in analyses per group. 
Arrows indicate representative points of staining (ICAM-1 expression).
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